Simvastatin reverses cardiac hypertrophy caused by disruption of the bradykinin 2 receptor

Canadian Journal of Physiology and Pharmacology

Volumn 86, Issue 9, 2008, Pages 633-642

  Osorio, Juan C ^a   Cheema, Faisal H ^a   Martens, Timothy P ^a   Mahmut, Naila ^b   Kinnear, Caroline ^b   Gonzalez, Ana M D ^a   Bonney, William ^a   Homma, Shunichi ^a   Liao, James K ^c   Mital, Seema ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Bradykinin; Cardiomyopathy; Echocardiography; Hypertrophy; Mitogen activated protein kinases; Nitric oxide; Simvastatin

Indexed keywords

BRADYKININ B2 RECEPTOR; CD31 ANTIGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; N(G) NITROARGININE METHYL ESTER; SIMVASTATIN; STRESS ACTIVATED PROTEIN KINASE;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL TISSUE; BLOOD PRESSURE; CELL SIZE; CONFERENCE PAPER; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEMODYNAMICS; HYPERTENSION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIGENS, CD31; BLOOD PRESSURE; CARDIOMEGALY; ENZYME INHIBITORS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTROPHY, LEFT VENTRICULAR; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASES; MYOCYTES, CARDIAC; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; RECEPTOR, BRADYKININ B1; RECEPTOR, BRADYKININ B2; SIGNAL TRANSDUCTION; SIMVASTATIN; STROKE VOLUME;

EID: 50849108861     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/Y08-068     Document Type: Conference Paper

References (37)

1. Abraham, S.S., Osorio, J.C., Homma, S., Wang, J., Thaker, H.M., Liao, J.K., et al. 2004. Simvastatin preserves cardiac function in genetically determined cardiomyopathy. J. Cardiovasc. Pharmacol. 43: 454-461. doi:10.1097/00005344-200403000-00018. PMID:15076231.
2. Adomeit, A., Graness, A., Gross, S., Seedorf, K., Wetzker, R., and Liebmann, C. 1999. Bradykinin B2 receptor-mediated mitogenactivated protein kinase activation in COS-7 cells requires dual signaling via both protein kinase C pathway and epidermal growth factor receptor transactivation. Mol. Cell. Biol. 19: 5289-5297. PMID:10409720.
3. Aronow, B.J., Toyokawa, T., Canning, A., Haghighi, K., Delling, U., Kranias, E., et al. 2001. Divergent transcriptional responses to independent genetic causes of cardiac hypertrophy. Physiol. Genomics, 6: 19-28. PMID:11395543.
4. Bauersachs, J., Galuppo, P., Fraccarollo, D., Christ, M., and Ertl, G. 2001. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation, 104: 982-985. doi:10.1161/hc3401. 095946. PMID:11524389.
5. Bell, R.M., and Yellon, D.M. 2003. Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J. Mol. Cell. Cardiol. 35: 185-193. doi:10.1016/S0022-2828(02) 00310-3. PMID:12606259.
6. Bernier, S.G., Haldar, S., and Michel, T. 2000. Bradykinin-regulated interactions of the mitogen-activated protein kinase pathway with the endothelial nitric-oxide synthase. J. Biol. Chem. 275: 30707-30715. doi:10.1074/jbc.M005116200. PMID:10899167.
7. Borghi, C., Prandin, M.G., Costa, F.V., Bacchelli, S., Degli Esposti, D., and Ambrosioni, E. 2000. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J. Cardiovasc. Pharmacol. 35: 549-555. doi:10. 1097/00005344-200004000-00006. PMID:10774784.
8. Brochu, I., Labonté, J., Bkaily, G., and D'Orléans-Juste, P. 2002. Role of endothelin receptors in the hypertensive state of kinin B(2) knockout mice subjected to a high-salt diet. Clin. Sci. (Lond.), 103: 380S-384S. PMID:12193127.
9. Brull, D., Dhamrait, S., Myerson, S., Erdmann, J., Regitz-Zagrosek, V., World, M., et al. 2001. Bradykinin B2BKR receptor polymorphism and left-ventricular growth response. Lancet, 358: 1155-1156. doi:10.1016/S0140-6736(01)06273-0. PMID:11597672.
10. Cervenka, L., Maly, J., Karasova, L., Simova, M., Vitko, S., and El-Dahr, S. S. 2001. Angiotensin II-induced hypertension in bradykinin B2 receptor knockout mice. Hypertension, 37(3): 967-973. PMID:11270390.
11. Cui, J., Melista, E., Chazaro, I., Zhang, Y., Zhou, X., Manolis, A.J., et al. 2005. Sequence variation of bradykinin receptors B1 and B2 and association with hypertension. J. Hypertens. 23: 55-62. doi:10.1097/00004872- 200501000-00013. PMID:15643125.
12. Dechend, R., Fiebeler, A., Park, J.-K., Muller, D.N., Theuer, J., Mervaala, E., et al. 2001. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Circulation, 104: 576-581. doi:10.1161/hc3001.092039. PMID:11479256.
13. Dhamrait, S.S., Payne, J.R., Li, P., Jones, A., Toor, I.S., Cooper, J.A., et al. 2003. Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension. Eur. Heart J. 24: 1672-1680. doi:10.1016/S0195-668X(03)00441-X. PMID:14499231.
14. Duka, A., Kintsurashvili, E., Duka, I., Ona, D., Hopkins, T. A., Bader, M., et al. 2008. Angiotensin-converting enzyme inhibition after experimental myocardial infarct: role of the kinin B1 and B2 receptors. Hypertension, 51(5): 1352-1357. doi:10.1161/HYPERTENSIONAHA.107.108506. PMID:18347228.
15. Emanueli, C., Maestri, R., Corradi, D., Marchione, R., Minasi, A., Tozzi, M.G., et al. 1999. Dilated and failing cardiomyopathy in bradykinin B2 receptor knockout mice. Circulation, 100: 2359-2365. PMID:10587341.
16. Fu, Y., Katsuya, T., Matsuo, A., Yamamoto, K., Akasaka, H., Takami, Y., et al. 2004. Relationship of bradykinin B2 receptor gene polymorphism with essential hypertension and left ventricular hypertrophy. Hypertens. Res. 27: 933-938. doi:10.1291/hypres.27.933. PMID:15894833.
17. Fujii, M., Wada, A., Tsutamoto, T., Ohnishi, M., Isono, T., and Kinoshita, M. 2002. Bradykinin improves left ventricular diastolic function under long-term angiotensin-converting enzyme inhibition in heart failure. Hypertension, 39: 952-957. doi:10.1161/01.HYP.0000015613.78314.9E. PMID:12019275.
18. Hallberg, P., Lind, L., Michaelsson, K., Karlsson, J., Kurland, L., Kahan, T., et al. 2003. B2 bradykinin receptor (B2BKR) polymorphism and change in left ventricular mass in response to antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J. Hypertens. 21: 621-624. doi:10.1097/ 00004872-200303000-00029. PMID:12640257.
19. Harris, M.B., Ju, H., Venema, V.J., Liang, H., Zou, R., Michell, B.J., et al. 2001. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. J. Biol. Chem. 276: 16587-16591. doi:10.1074/jbc.M100229200. PMID:11340086.
20. Hayashida, W., Kihara, Y., Yasaka, A., Inagaki, K., Iwanaga, Y., and Sasayama, S. 2001. Stage-specific differential activation of mitogen-activated protein kinases in hypertrophied and failing rat hearts. J. Mol. Cell. Cardiol. 33: 733-744. doi:10.1006/jmcc.2001.1341. PMID:11273726.
21. Hayashidani, S., Tsutsui, H., Shiomi, T., Suematsu, N., Kinugawa, S., Ide, T., et al. 2002. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation, 105: 868-873. doi:10.1161/hc0702.104164. PMID: 11854129.
22. Ishigai, Y., Mori, T., Ikeda, T., Fukuzawa, A., and Shibano, T. 1997. Role of bradykinin-NO pathway in prevention of cardiac hypertrophy by ACE inhibitor in rat cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 273: H2659-H2663.
23. Laufs, U., and Liao, J.K. 1998. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273: 24266-24271. doi:10.1074/jbc.273.37.24266. PMID:9727051.
24. Laufs, U., La Fata, V., Plutzky, J., and Liao, J.K. 1998. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation, 97: 1129-1135. PMID:9537338.
25. Liang, Q., and Molkentin, J.D. 2003. Redefining the roles of p38 and JNK signaling in cardiac hypertrophy: dichotomy between cultured myocytes and animal models. J. Mol. Cell. Cardiol. 35: 1385-1394. doi:10.1016/j.yjmcc.2003. 10.001. PMID:14654364.
26. Liesmaa, I., Kokkonen, J.O., Kovanen, P.T., and Lindstedt, K.A. 2007. Lovastatin induces the expression of bradykinin type 2 receptors in cultured human coronary artery endothelial cells. J. Mol. Cell. Cardiol. 43: 593-600. doi:10.1016/j.yjmcc.2007.08.007. PMID:17900611.
27. Liu, P.P., Mak, S., and Stewart, D. 1999. Potential role of the microvasculature in progression of heart failure. Am. J. Cardiol. 84(4A): 23L-26L. doi:10.1016/S0002-9149(99)00361-6. PMID: 10480442.
28. Luckhoff, A., Busse, R., Winter, I., and Bassenge, E. 1987. Characterization of vascular relaxant factor released from cultured endothelial cells. Hypertension, 9: 295-303. PMID:3102369.
29. Madeddu, P., Varoni, M.V., Palomba, D., Emanueli, C., Demontis, M.P., Glorioso, N., et al. 1997. Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. Circulation, 96: 3570-3578. PMID:9396457.
30. Mital, S., Magneson, A., Loke, K.E., Liao, J., Forfia, P.R., and Hintze, T.H. 2000a. Simvastatin acts synergistically with ACE inhibitors or amlodipine to decrease oxygen consumption in rat hearts. J. Cardiovasc. Pharmacol. 36: 248-254. doi:10.1097/00005344-200008000-00016. PMID:10942168.
31. Mital, S., Zhang, X., Zhao, G., Bernstein, R.D., Smith, C.J., Fulton, D.L., et al. 2000b. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am. J. Physiol. Heart Circ. Physiol. 279: H2649-H2657. PMID:11087217.
32. Mukhin, Y.V., Garnovsky, E.A., Ullian, M.E., and Garnovskaya, M.N. 2003. Bradykinin B2 receptor activates extracellular signal-regulated protein kinase in mIMCD-3 cells via epidermal growth factor receptor transactivation. J. Pharmacol. Exp. Ther. 304: 968-977. doi:10.1124/jpet.102.043943. PMID:12604671.
33. Suehiro, K., Takuma, S., Cardinale, C., Hozumi, T., Shimizu, J., Yano, H., et al. 2001. Assessment of segmental wall motion abnormalities using contrast two-dimensional echocardiography in awake mice. Am. J. Physiol. Heart Circ. Physiol. 280: H1729-H1735. PMID:11247786.
34. Sugden, P.H. 2001. Mechanotransduction in cardiomyocyte hypertrophy. Circulation, 103: 1375-1377. PMID:11245638.
35. Takenaka, M., Hirade, K., Tanabe, K., Akamatsu, S., Dohi, S., Matsuno, H., et al. 2003. Simvastatin stimulates VEGF release via p44/p42 MAP kinase in vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 301: 198-203. doi:10.1016/S0006-291X(02)03014-0. PMID:12535662.
36. Tonolo, G., Melis, M.G., Formato, M., Angius, M.F., Carboni, A., Brizzi, P., et al. 2000. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur. J. Clin. Invest. 30: 980-987. doi:10.1046/j.1365-2362.2000.00735.x. PMID:11114960.
37. Yang, C.-M., Chien, C.-S., Ma, Y.-H., Hsiao, L.-D., Lin, C.-H., and Wu, C.-B. 2003. Bradykinin B 2 receptor-mediated proliferation via activation of the Ras/Raf/MEK/MAPK pathway in rat vascular smooth muscle cells. J. Biomed. Sci. 10: 208-218. PMID:12595757.